At the end of follow-up, serum CEA levels significantly rose in 48 of the 204 resectable CRC patients including 17 of the 74 (23.0%) immunotherapy group patients and 31 of the 130 (23.8%) control group patients (P = 0.58). Here, CEACAM5 is linked to colorectal carcinoma.